Atlas Trials

A Multicenter, Randomized Clinical Trail Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After the 1st-line Chemotherapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer(Overstep)

Clinical trial NCT02597868 · UNKNOWN

Trial details

NCT number
NCT02597868
Sponsor
Zhejiang Cancer Hospital
Status
UNKNOWN
Phase
Not Applicable
Study type
INTERVENTIONAL
Breast Cancer
Start date
2013-01-01
Primary completion
2016-07-01
Enrollment
132

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.